Gentian Diagnostics (GENT) Pareto Securities Healthcare Conference Presentation summary

Company overview and market positioning

• Targets a $2.2B serviceable diagnostic segment with 5–10% annual growth.

• Operates a lean business model with global strategic partnerships and OEM agreements.

• Listed on Euronext Oslo Børs and maintains high quality and ESG standards.

• Focuses on in-house R&D and commercial phase profitability.

Value proposition and strategy

• Converts slow diagnostic biomarkers to high-throughput platforms for faster results and up to 10x efficiency gains.

• Addresses unmet needs in new biomarkers, portfolio gaps, and regulatory or supply issues.

• Differentiates through world-class R&D, production, data generation, and regulatory support.

Product portfolio and disease focus

• Key areas: inflammation & infection, kidney disease, and heart failure.

• Established products include Cystatin C, Canine CRP, fCAL®, and GCAL®.

• Pipeline includes NT-proBNP and other novel assays.